Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder characterized by the presence of auto-antibodies to nuclear antigens, immune complex deposition, and subsequent tissue destruction. Early studies in twins suggested that SLE has, at least in part, a genetic basis, and a role for class II alleles in the major histocompatibility complex has been known for over 30 years. Through both linkage studies and candidate gene studies, numerous additional genetic risk factors have been identified. The recent publication of two SNP-based genome-wide association studies (GWAS) has resulted in the confirmation of a number of previously identified genetic risk loci and has identified new previously unappreciated loci conferring risk for development of SLE. A role for gene copy number variation (CNV) in SLE has also been appreciated through studies of the complement component 4 (C4) loci and more recent work in the IgG Fc receptor loci. The availability of large SNP-based GWAS datasets will undoubtedly lead to the genome-wide analysis and identification of copy number variants related to genetic susceptibility for development of SLE. We review current studies of CNV in SLE susceptibility that include reports of association between SLE and CNV in C4, IgG Fc receptors, TLR7, and CCL3L1.

1.
Ahuja SK, Kulkarni H, Catano G, Agan BK, Camargo JF, et al: CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med 14:413–420 (2008).
2.
Aitman TJ, Dong R, Vyse TJ, Norsworthy PJ, Johnson MD, et al: Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 439:851–855 (2006).
3.
Alarcon GS, McGwin G Jr, Petri M, Ramsey-Goldman R, Fessler BJ, et al: Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort. PLoS Med 3:1949–1956 (2006).
4.
Beckmann JS, Estivill X, Antonarakis SE: Copy number variants and genetic traits: closer to the resolution of phenotypic to genotypic variability. Nat Rev Genet 8:639–646 (2007).
5.
Blauw HM, Veldink JH, van Es MA, van Vught PW, Saris CG, et al: Copy-number variation in sporadic amyotrophic lateral sclerosis: a genome-wide screen. Lancet Neurol 7:319–326 (2008).
6.
Breunis WB, van Mirre E, Bruin M, Geissler J, de Boer M, et al: Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood 111:1029–1038 (2008).
7.
Brown EE, Edberg JC, Kimberly RP: Fc receptor genes and the systemic lupus erythematosus diathesis. Autoimmunity 40:567–581 (2007).
8.
Bux J: Human neutrophil alloantigens. Vox Sang 94:277–285 (2008).
9.
Clark MR, Liu L, Carkson SB, Ory PA, Golstein IM: An abnormality of the gene that encodes neutrophil Fc receptor III in a patient with systemic lupus erythematosus. J Clin Invest 86:341–346 (1990).
10.
Clark RA, Klebanoff SJ: Role of the classical and alternative complement pathways in chemotaxis and opsonization: studies of human serum deficient in C4. J Immunol 120:1102–1108 (1978).
11.
Cook HT, Botto M: Mechanisms of disease: the complement system and the pathogenesis of systemic lupus erythematosus. Nat Clin Pract Rheum 2:330–337 (2006).
12.
Coxon A, Cullere X, Knight S, Sethi S, Wakelin MW, et al: FcγRIII mediates neutrophil recruitment to immune complexes: a mechanism for neutrophil accumulation in immune-mediated inflammation. Immunity 14:693–704 (2001).
13.
Croker JA, Kimberly RP: Genetics of susceptibility and severity in systemic lupus erythematosus. Curr Opin Rheumatol 17:529–537 (2005).
14.
Cronin S, Berger S, Ding J, Schymick JC, Washecka N, et al: A genome-wide association study of sporadic ALS in a homogenous Irish population. Hum Mol Genet 17:769–774 (2008).
15.
de Haas M, Kleijer M, van Zwieten R, Roos D, von dem Borne AE: Neutrophil FcγRIIIb deficiency, nature and clinical consequences: a study of 21 individuals from 14 families. Blood 86:2403–2412 (1995).
16.
Dolan MJ, Kulkarni H, Camargo JF, He W, Smith A, et al: CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol 8:1324–1336 (2007).
17.
Edberg JC, Kimberly RP: Modulation of Fcγ and complement receptor function by the glycosyl-phosphatidylinositol-anchored form of FcγRIII. J Immunol 152:5826–5835 (1994).
18.
Eichler EE, Nickerson Da, Altshuler D, Bowcock AM, Brooks LD, et al: Completing the map of human genetics variation. Nature 447:161–165 (2007).
19.
Fanciulli M, Norsworthy PJ, Petretto E, Dong R, Harper L, et al: FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific autoimmunity. Nat Genet 39:721–723 (2007).
20.
Fellermann K, Stange DE, Schaeffeler E, Schmalzl H, Wehkamp J, et al: A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet 79:439–448 (2006).
21.
Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, et al: The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307:1434–1440 (2005).
22.
Gregersen PK, Behrens TW: Genetics of autoimmune diseases – disorders of immune homeostasis. Nat Rev Genet 7:917–928 (2006).
23.
Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, et al: Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 40:204–210 (2008).
24.
Hauptmann G, Grosshans E, Heid E: Lupus erythematosus syndrome and complete deficiency of the fourth component of complement. Boll Ist Sieroter Milan 53:228 (1974).
25.
Hochberg MC: The epidemiology of systemic lupus erythematosus; in Wallace DJ, Hahn BH (eds): Dubois’ Lupus Erythematosus, pp 49–65 (Williams and Wilkins, Baltimore 1997a).
26.
Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725 (1997b).
27.
Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, et al: Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 358:900–909 (2008).
28.
Huizinga TW, Dolman KM, van der Linden NJ, Kleijer M, von dem Borne AE, et al: Phosphatidylinositol-linked FcrIII mediates exocytosis of neutrophil granule proteins but does not mediate initiation of the respiratory burst. J Immunol 144:1432–1437 (1990a).
29.
Huizinga TW, Kuijpers RW, Kleijer M, Schulpen TW, Cuypers HT, et al: Maternal genomic neutrophil FcRIII deficiency leading to neonatal isoimmune neutropenia. Blood 76:1927–1932 (1990b).
30.
Hundt M, Schmidt RE: The glycosylphosphatidylinositol-linked Fc receptor III represents the dominant receptor structure for immune complex activation of neutrophils. Eur J Immunol 22:811–816 (1992).
31.
Izui S, Iwamoto M, Fossati L, Merino R, Takahashi S, Ibnou-Zekri N: The Yaa gene model of systemic lupus erythematosus. Immunol Rev 144:137–156 (1995).
32.
Kelley J, Johnson MR, Alarcon GS, Kimberly RP, Edberg JC: Variation in the relative copy number of the TLR7 gene in patients with systemic lupus erythematosus and healthy control subjects. Arthritis Rheum 56:3375–3378 (2007).
33.
Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, et al: The human genome browswer at UCSC. Genome Res 12:996–1006 (2002).
34.
Kissel K, Hofmann C, Gittinger FS, Daniels G, Bux J: HNA-1a, HNA-1b and HNA-1c (NA1, NA2, SH) frequencies in African and American blacks and Chinese. Tissue Antigens 56:143–148 (2000).
35.
Kocher M, Siegel ME, Edberg JC, Kimberly RP: Cross-linking of Fc gamma receptor IIa and Fc gamma receptor IIIb induces different proadhesive phenotypes on human neutrophils. J Immunol 159:3940–3948 (1997).
36.
Koene HR, Kleijer M, Roos D, de Haas M, Von dem Borne AE: Fc γRIIIB gene duplication: evidence for presence and expression of three distinct Fc γRIIIB genes in NA(1+,2+)Sh(+) individuals. Blood 91:673–679 (1998).
37.
Lau CS, Yin G, Mok MY: Ethnic and geographical differences in systemic lupus erythematosus: an overview. Lupus 15:715–719 (2006).
38.
Mamtani M, Rovin B, Brey R, Camargo JF, Kulkarni H, et al: CCL3L1 gene-containing segmental duplications and polymorphisms in CCR5 affect risk of systemic lupus erythematosus. Ann Rheum Dis 67:1076–1083 (2008).
39.
Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, et al: Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 82:477–488 (2008).
40.
Matarin M, Simon-Sanchez J, Fung HC, Scholz S, Gibbs R, et al: Structural genomic variation in ischemic stroke. Neurogenetics 9:101–108 (2008).
41.
McKinney C, Merriman ME, Chapman PT, Gow PJ, Harrison AA, et al: Evidence for an influence of chemokine ligand 3-like 1 (CCL3L1) gene copy number on susceptibility to rheumatoid arthritis. Ann Rheum Dis 67:409–413 (2008).
42.
Mestas J, Hughes CC: Of mice and not men: differences between mouse and human immunology. J Immunol 172:2731–2738 (2004).
43.
Murphy ED, Roths JB: A Y chromosome associated factor in strain BXSB producing accelerated autoimmunity and lymphoproliferation. Arthritis Rheum 22:1188–1194 (1979).
44.
Negi VS, Elluru S, Siberil S, Graff-Dubois S, Mouthon L, et al: Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol 27:233–245 (2007).
45.
Nimmerjahn F, Ravetch JV: Fc-receptors as regulators of immunity. Adv Immunol 96:179–204 (2007).
46.
Ohno S: Evolution by Gene Duplication (Springer, Berlin 1970).
47.
Park-Min KH, Serbina NV, Yang W, Ma X, Krystal G, et al: FcgRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 26:67–78 (2007).
48.
Pisitkun P, Dean JA, Difilippantonio MJ, Tarasenko T, Satterthwait AB, Bolland S: Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312:1669–1672 (2006).
49.
Samuelsson A, Towers TL, Ravetch JV: Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484–486 (2001).
50.
Sarzi-Puttini P, Atzeni F, Iaccarino L, Doria A: Environment and systemic lupus erythematosus: an overview. Autoimmunity 38:465–472 (2005).
51.
Schaller JG, Gilliland BG, Ochs HD, Leddy JP, Agodoa LC, Rosenfeld SI: Severe systemic lupus erythematosus with nephritis in a boy with deficiency of the fourth component of complement. Arthritis Rheum 20:1519–1525 (1977).
52.
Schnell M, Halligan G, Herman J: A new granulocyte antibody directed at a high-frequency antigen causing neonatal alloimmune neutropenia. Transfusion 29:46S (1989).
53.
Siragam V, Crow AR, Brinc D, Song S, Freedman J, Lazarus AH: Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 12:688–692 (2006).
54.
Stefansson H, Rujescu D, Cichon S, Ingason A, Steinberg S, et al: Large recurrent microdeletions associated with schizophrenia. Nature 455:232–236 (2008).
55.
Stroncek D: Neutrophil alloantigens. Transfus Med Rev 16:67–75 (2002).
56.
Takeda K, Kaisho T, Akria S: Toll-like receptors. Annu Rev Immunol 21:335–376 (2003).
57.
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, et al: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277 (1982).
58.
Vyse TJ: Understanding lupus: fishing genes out of mice and men. Immunity 28:8–10 (2008).
59.
Walport MJ: Complement, first of two parts. N Engl J Med 344:1058–1066 (2001a).
60.
Walport MJ: Complement, second of two parts. N Engl J Med 344:1140–1144 (2001b)
61.
Walport MJ: Complement and systemic lupus erythematosus. Arthritis Res 4:S279–S293 (2006).
62.
Yang Y, Chung EK, Wu YL, Savelli SL, Nagaraja HN, et al: Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am J Hum Genet 80:1037–1054 (2007).
63.
Yang Z, Mendoza AR, Welch TR, Zipf WB, Yu CY: Modular variations of the human major histocompatibility complex class III genes for serine/threonine kinase RP, complement component C4, steroid 21-hydroxylase CYP21, and tenascin TNX (the RCCX module). J Biol Chem 274:12147–12156 (1999).
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.